Saqib IslamFounder

United States - Westport, Connecticut

With more than 25 years of global leadership experience across biopharma and healthcare finance, I’m passionate about building companies that deliver life‑changing medicines for patients. As Chief Executive Officer of Beeline Medicines, I’m focused on defining new treatment paradigms for people living with autoimmune and inflammatory diseases, starting with lupus.

Most recently, I served as CEO and member of the Board of SpringWorks Therapeutics, where I was proud to build and lead the company from its founding in 2017 through its evolution from a clinical-stage startup into a fully integrated, global, publicly traded commercial organization. Along the way, we built a differentiated pipeline and commercial platform, and brought two novel, best‑in‑class therapies through global regulatory approvals and launches, with these medicines now serving patients living with devastating rare diseases around the world. My time at SpringWorks culminated in the company’s $3.9 billion acquisition by Merck KGaA, Darmstadt, Germany in 2025.

Earlier in my career, I held executive leadership roles at Moderna Therapeutics and Alexion Pharmaceuticals and previously served in senior leadership positions in the global investment banking divisions of Morgan Stanely and Credit Suisse Securities. I currently serve on the Boards of Beeline Medicines and ARS Pharmaceuticals.

I care deeply about rigorously advancing science to help shape the future of care and to make a meaningful impact for patients.